Crestor (rosuvastatin) has been approved for two additional indications: heterozygous familial hypercholesterolaemia in children aged 10–17 years and primary prevention of major cardiovascular events in high-risk adults.
Children prescribed Crestor must be at least Tanner Stage II (boys) or 1-year post-menarche (girls).
The prevention indication is based on a post-hoc analysis of the JUPITER study, which revealed that rosuvastatin 20mg daily significantly reduced the combined risk of cardiovascular death, stroke and myocardial infarction in high-risk patients. This trial showed a small increase in the risk of diabetes in patients taking rosuvastatin, compared with those taking placebo.
Further information: AstraZeneca